← Back to Search

Cognitive Behavioral Therapy

Virtual Cognitive Behavioural Therapy for Psychosis for Schizophrenia

N/A
Recruiting
Led By Michael W Best, PhD
Research Sponsored by University of Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline to follow-up (6 months post treatment)
Awards & highlights

Study Summary

This trial is testing whether cognitive behavioral therapy can help people with schizophrenia who are currently experiencing symptoms of psychosis.

Eligible Conditions
  • Schizophrenia
  • Psychosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline to follow-up (6 months post treatment)
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from baseline to follow-up (6 months post treatment) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Positive and Negative Syndrome Scale (PANSS) Total Score
Secondary outcome measures
Beliefs About Paranoia Scale (BAPS)
Beliefs About Voices Questionnaire (BAVQ)
Brief Core Schema Scale (BCSS)
+10 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Virtual Cognitive Behavioural Therapy for PsychosisExperimental Treatment1 Intervention
CBT will be delivered according to an established manual that the PI has previously used successfully for in-person treatment. Treatment will consist of individual sessions with a psychologist employed by the University of Toronto for 1-hour per week for 6-months, or by one of the listed clinical graduate students under his supervision. All treatment will be delivered virtually in the participant's home using the online platform Zoom which is PHIPA/PIPEDA compliant. If participants do not have the technology required for virtual sessions, then a tablet will be loaned to them for the duration of treatment. This treatment will be delivered in addition to usual care and no changes to usual care will be required.
Group II: Treatment as UsualActive Control1 Intervention
Participants continue with their regular standard of care without the addition of virtual Cognitive Behavioural Therapy for Psychosis.

Find a Location

Who is running the clinical trial?

University of TorontoLead Sponsor
689 Previous Clinical Trials
1,018,583 Total Patients Enrolled
4 Trials studying Schizophrenia
632 Patients Enrolled for Schizophrenia
Ontario Shores Centre for Mental Health SciencesOTHER
12 Previous Clinical Trials
2,078 Total Patients Enrolled
3 Trials studying Schizophrenia
420 Patients Enrolled for Schizophrenia
Michael W Best, PhDPrincipal InvestigatorUniversity of Toronto
1 Previous Clinical Trials
40 Total Patients Enrolled
1 Trials studying Schizophrenia
40 Patients Enrolled for Schizophrenia

Media Library

Virtual Cognitive Behavioural Therapy for Psychosis (Cognitive Behavioral Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04752449 — N/A
Schizophrenia Research Study Groups: Virtual Cognitive Behavioural Therapy for Psychosis, Treatment as Usual
Schizophrenia Clinical Trial 2023: Virtual Cognitive Behavioural Therapy for Psychosis Highlights & Side Effects. Trial Name: NCT04752449 — N/A
Virtual Cognitive Behavioural Therapy for Psychosis (Cognitive Behavioral Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04752449 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
American Journal of PsychiatryJournal
Effects of Antipsychotic Medications on Psychosocial Functioning in Patients with Chronic Schizophrenia: Findings from the NIMH CATIE Study
Swartz, Marvin S., M.D., Diana O. Perkins M.D., M.P., T. Scott Stroup M.D., M.P., Sonia M. Davis Dr.P.H., George Capuano Ph.D., Robert A. Rosenheck M.D., Fred Reimherr M.D., et al.. 2007. “Effects of Antipsychotic Medications on Psychosocial Functioning in Patients with Chronic Schizophrenia: Findings from the NIMH CATIE Study”. American Journal of Psychiatry. American Psychiatric Association Publishing. doi:10.1176/ajp.2007.164.3.428.
Schizophrenia ResearchJournal
Development of the Davos Assessment of Cognitive Biases Scale (DACOBS)
van der Gaag, Mark, Chantal Schütz, Angela ten Napel, Yulia Landa, Philippe Delespaul, Maarten Bak, Wolfgang Tschacher, and Marc de Hert. 2013. “Development of the Davos Assessment of Cognitive Biases Scale (DACOBS)”. Schizophrenia Research. Elsevier BV. doi:10.1016/j.schres.2012.12.010.
Psychological MedicineJournal
Adapted Cognitive–behavioural Therapy Required for Targeting Negative Symptoms in Schizophrenia: Meta-analysis and Meta-regression
Velthorst, E., M. Koeter, M. van der Gaag, D. H. Nieman, A.-K. J. Fett, F. Smit, A. B. P. Staring, C. Meijer, and L. de Haan. 2014. “Adapted Cognitive–behavioural Therapy Required for Targeting Negative Symptoms in Schizophrenia: Meta-analysis and Meta-regression”. Psychological Medicine. Cambridge University Press (CUP). doi:10.1017/s0033291714001147.
The Journal of Clinical PsychiatryJournal
The Economic Burden of Schizophrenia in the United States in 2002
Wu, Eric Q., Howard G. Birnbaum, Lizheng Shi, Daniel E. Ball, Ronald C. Kessler, Matthew Moulis, and Jyoti Aggarwal. 2005. “The Economic Burden of Schizophrenia in the United States in 2002”. The Journal of Clinical Psychiatry. Physicians Postgraduate Press, Inc. doi:10.4088/jcp.v66n0906.
~14 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top